Navigation Links
Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/6/2008

- Management to host call and webcast today at 5:00 p.m. Eastern to discuss

financial results and recent business highlights -

SAN DIEGO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced unaudited financial results for the three and nine months ended September 30, 2008.

Three Months Ended September 30, 2008

As of September 30, 2008, Orexigen held $52.5 million in cash and cash equivalents and an additional $47.6 million in investment securities, available-for-sale, for a total balance of $100.1 million. Orexigen holds primarily treasury-backed securities, money market funds and agency instruments guaranteed by the U.S. federal government. The Company's exposure to corporate debt instruments is modest, and comprised exclusively of commercial paper rated at least A1+/P1, with average maturity less than 90 days. The Company does not have any auction rate securities on its balance sheet.

For the three months ended September 30, 2008, Orexigen reported a net loss of $24.8 million, or $0.72 per share attributable to common stockholders, as compared to a net loss of $14.5 million, or $0.54 per share attributable to common stockholders, for the comparable period in 2007.

Total operating expenses for the three months ended September 30, 2008 were $25.1 million compared to $15.6 million for the comparable period in 2007. The increased operating expenses were due primarily to an $8.6 million increase in research and development expenses in connection with the Company's Contrave(R) Phase 3 clinical trials, related proprietary product for
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
5. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
6. CV Therapeutics Reports 2008 Third Quarter Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
9. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
10. Nile Therapeutics to Present at Two Upcoming Investor Conferences
11. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... The laboratory information management systems market is ... of technological advancements due to factors such as rising ... integrate healthcare systems, and increasing government support for adoption ... Key players in the market focus on technological advancements ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited to ... on probiotics in San Diego, CA. , The Scripps ... health care professionals. This year’s pre-conference seminar was held on ... Dr. Leyer spoke about the emerging topics and science in ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... , April 22 As evidence of ... lifetime of physical activity, Smith & Nephew ( SNN, ... unprecedented testing on its VERILAST technology for knee replacement ... the company,s LEGION™ knee replacement, VERILAST technology produced an ...
... YORK and SCOTTSDALE, Ariz. , April ... NBS ), an international biopharmaceutical,company with operations in the ... wholly owned subsidiary of IR BioSciences Holdings, Inc.,(OTC Bulletin ... a,Collaborative Research Agreement, focused on the development of an ...
... ... Follow-on Biologics in Chicago. , ... Chicago (Vocus) April 22, 2010 -- Therapeutic Proteins Inc. (TPI) ... manufacturing facility constructed to meet U.S. Food and Drug Administration (FDA) requirements. The Chicago ...
Cached Biology Technology:Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 2Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 3Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 4Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee 5NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 2NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 3NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 4NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 5NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 6NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology 7Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 2Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 3Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S. 4
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) ... Wearable Technologies Market and Applications, Opportunities, Industry Analysis, ... 2014-2020" report to their offering. , ... can be worn on the user,s body and ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... Microbial Genomes (IMG) data management system, a resource provided ... has now been released. Hosted by the U.S. Department ... built a popular following as reflected in the overwhelming ... full. DOE JGI has added a fall session, September ...
... Copenhagen, 5 December 2007 - If you needed to ... a fish from Fiji, would you know where to ... specimens from a particular time or place right now ... Biodiversity Information Facility (GBIF), Biodiversity Information Standards (TDWG) and ...
... climate change, high energy prices, globalization, and urbanization ... and consumption, according to a new report by ... a result, global food demand and prices are ... of poor people in developing countries. The report, ...
Cached Biology News:GBIF making the search for biodiversity research resources easier 2Rising food prices threaten world's poor people 2Rising food prices threaten world's poor people 3Rising food prices threaten world's poor people 4